Recent Quotes (30 days)

You have no recent quotes
chg | %

Transition Therapeutics Inc (USA)  

(Public, NASDAQ:TTHI)   Watch this stock  
Find more results for TTHI
0.788
-0.042 (-5.06%)
Apr 29 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.76 - 0.86
52 week 0.74 - 9.30
Open 0.83
Vol / Avg. 30,264.00/84,186.00
Mkt cap 27.86M
P/E     -
Div/yield     -
EPS -0.52
Shares 38.88M
Beta 1.76
Inst. own 24%
May 10, 2016
Q3 2016 Transition Therapeutics Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Mar 9, 2016
Transition Therapeutics Inc at Cowen Health Care Conference
Feb 9, 2016
Q2 2016 Transition Therapeutics Inc Earnings Call
Feb 9, 2016
Q2 2016 Transition Therapeutics Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '15) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -20.41% -86.61%
Return on average equity -25.36% -107.14%
Employees 18 -
CDP Score - -

Address

101 College St Suite 220
TORONTO, ON M5G 1L7
Canada
+1-416-2607770 (Phone)
+1-416-2602886 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Transition Therapeutics Inc. is a product-focused biopharmaceutical company. The Company's principal business activity is the researching and developing of therapeutic agents. The Company is developing therapeutics for central nervous system (CNS) and metabolic disease indications. The Company's technologies are focused on the treatment of agitation and aggression in Alzheimer's disease and diabetes. The Company's subsidiary, Transition Therapeutics Ireland Limited (Transition Ireland), is developing two drug candidates: neuropsychiatric candidate ELND005 and androgen deficiency candidate TT701. The Company's subsidiary, Waratah Pharmaceuticals Inc. (Waratah), is developing diabetes drug candidate TT401. The Company's other two entities provide development services in support of the clinical and non-clinical activities of Transition Ireland and Waratah.

Officers and directors

Tony F. Cruz Ph.D. Chairman of the Board, Chief Executive Officer
Bio & Compensation  - Reuters
Carl Damiani President, Chief Operating Officer
Age: 40
Bio & Compensation  - Reuters
Nicole Rusaw Chief Financial Officer
Age: 39
Bio & Compensation  - Reuters
Bruce Connop Vice President - Non-Clinical & Pharmaceutical Development
Age: 43
Bio & Compensation  - Reuters
Aleksandra Pastrak Vice President - Clinical Development and Medical Officer
Age: 46
Bio & Compensation  - Reuters
Louis Alexopoulos Secretary
Bio & Compensation  - Reuters
Michael Richard Dwyer Ashton Lead Independent Director
Age: 69
Bio & Compensation  - Reuters
Paul Baehr Independent Director
Age: 69
Bio & Compensation  - Reuters
Christopher M. Henley Independent Director
Age: 52
Bio & Compensation  - Reuters
Gary W. Pace Ph.D. Independent Director
Age: 67
Bio & Compensation  - Reuters